Introduction {#Sec1}
============

Mobility impairment and assistive mobility technology {#Sec2}
-----------------------------------------------------

Mobility impairment is the leading cause of disability in the UK, accounting for 52% of reported disabilities \[[@CR1]\]. Mobility impairments arise from a vast array of different disabilities, conditions, injuries and illnesses. However, they can be classified broadly as either congenital (i.e. from birth) or acquired (i.e. occurring later in life). Whether a disability is present from birth or acquired later on in life significantly influences individual adaptation. For instance, individuals with congenital disabilities exhibit higher degrees of life satisfaction, self-identity and self-efficacy (related to their disability) than individuals who have had to adapt to acquired disability \[[@CR2]\]. Adaptation to disability is influenced by self-concept and disability identity, which in turn are related to the onset of disability \[[@CR2]\].

Common congenital conditions which can impact mobility include cerebral palsy (CP) and spina bifida (SB). CP refers to a number of conditions caused by damage to the parts of the brain which control movement, balance and posture, and can be caused either by abnormal brain development or trauma. CP is symptomized by varying degrees of permanent movement disorder, including poor coordination, muscle stiffness/weakness and involuntary movements. SB affects the development of the spine and spinal cord before birth, and can result in leg weakness and paralysis. There are three types of SB: myelomeningocele, meningocele and SB occulta.

Both congenital and acquired mobility impairments may necessitate the use of assistive technology to alleviate impairments. Assistive technology refers to a wide array of products and services which enhance functioning, participation and promote independence for people who have disabilities. The Medicines and Healthcare Products Regulatory Agency defines assistive technology as any device "intended to compensate for or alleviate an injury, handicap or illness or to replace a physical function" \[[@CR3]\]. Assistive technology, such as wheelchairs, are an "essential component for inclusive sustainable development" \[[@CR4]\], and can enhance the fundamental freedoms and equality of opportunity for people with mobility impairments and other disabilities. The United Nations (UN) states that access to appropriate and affordable assistive technology is a basic human right \[[@CR5]\]; the UN Convention on the Rights of Persons with Disabilities has been ratified by 175 Member States, who are obligated to ensure that affordable assistive technology is available to all individuals in need. However, The World Health Organization (WHO) estimates that only 10% of people who need assistive technology have access to it \[[@CR6]\], and there remain persistent challenges in the equitable provision of assistive technology, particularly in developing countries. One of the keys issues is in assessing the costs and benefits of different assistive technologies, and developing evidence-based approaches to provision which make best use of limited resources to maximise the outcomes of people with disabilities.

The National Health Service (NHS) in the UK spends almost £200million per year on wheelchairs alone \[[@CR7]\], thus there is an imperative to ensure that assistive mobility technologies (AMTs) such as wheelchairs and other mobility-enhancing interventions are provided in an evidence-based manner, utilising evidence of cost-effectiveness to guide service commissioning.

Economic evaluation and quality-adjusted life years {#Sec3}
---------------------------------------------------

Methods of economic evaluation are now routinely embedded in the evaluation of health technologies, and used to estimate the cost of incremental benefits associated with new and alternative health interventions. Cost-utility analysis, specifically estimation of cost per quality-adjusted life years (QALYs), has become the predominant form of economic evaluation for new health technologies in the UK, in part due to the National Institute for Health and Care Excellence's (NICE) advocacy for this approach \[[@CR8]\]. The QALY framework has become increasingly influential in health policy as a theoretically universal and generic approach to measuring benefits via a single common outcome.

In order to calculate QALYs, health state utility values are needed. These values are most commonly derived from preference-based measures (PBMs) of health-related quality of life (HRQoL). HRQoL is a subjective and multi-dimensional construct defined as the perceived impact of health status on quality of life, including physical, psychological and social functioning. PBMs of HRQoL are used to assess the social desirability and utility values associated with different states of health.

As the descriptive systems and value sets of generic PBMs are usually derived from adult samples of the general population, a common criticism is that their genericity limits relevance and sensitivity in certain conditions \[[@CR9]\]. Moreover, in health states where quality of life takes precedent over quantity of life (e.g. chronic illness, life-limiting conditions and disability), QALYs derived from generic PBMs can devalue the effectiveness of an intervention \[[@CR10]\].

Use of preference-based measures in the context of mobility impairment {#Sec4}
----------------------------------------------------------------------

The accuracy of a QALY estimate is subject to the sensitivity and applicability of the measurement tool used to generate the utility data. PBMs have been found to be inconsistent in both congenital and acquired mobility impairments \[[@CR11]--[@CR13]\], furthermore different PBMs produce significantly different results for AMT users \[[@CR14], [@CR15]\].

Previous research shows that patients with congenital mobility impairments do not necessarily consider mobility to have a major impact on their HRQoL when suitable adaptations (such as AMT) are available \[[@CR16], [@CR17]\]. However, general population PBM value sets heavily impact estimation of HRQoL when ability to walk is affected. As an example, using the NICE approved UK value set for the EuroQoL five-dimension (three level version) (EQ-5D-3 L), the lowest possible mobility level ('confined to bed') has a disutility of − 0.664, meaning that an individual who is unable to walk but is otherwise mobile using AMT can achieve a maximum utility value of 0.336 (0 = death; 1 = perfect health), even if they have no other HRQoL impacts. This raises the questions as to whether existing PBMs are a valid source of utility values in mobility impaired populations, particularly AMT users.

The validity of PBMs can be tested by comparing results across groups of patients and by comparing generic PBMs with condition-specific measures. For instance, the EQ-5D-3 L and the Health Assessment Questionnaire (HAQ; an outcome measure for rheumatoid arthritis) both measure health status in significantly different ways \[[@CR18]\], suggesting that the EQ-5D-3 L is lacking consideration of important health impacts associated with rheumatoid arthritis. These issues are partly due to the insensitivity of the EQ-5D-3 L 'mobility' dimension to accurately assess the varied impacts of rheumatoid arthritis on mobility \[[@CR19]\]. Similarly, the limited level choices on the EQ-5D-3 L have been found to cause some individuals with mobility impairments to choose levels which are more or less severe than their actual state, such as using 'I am confined to bed' to substitute being confined 'to an electric wheelchair' \[[@CR20]\]. The updated five level version of the EQ-5D (EQ-5D-5 L) is unlikely to address this issue as the five level choices still focus on walking and do not take account of alternative methods of mobility.

Even simple generic measures of health status, such as the single question self-reported health (SRH) scale (i.e. "in general, would you say your health is excellent, very good, good, fair, or poor?"), exhibit only limited correlation with PBMs such as the Health Utilities Index (HUI) 3 and Assessment of Quality of Life (AQoL) in the context of SB \[[@CR21]\] and CP \[[@CR22]\]. Likewise, for individuals with spinal cord injuries, the wording of the 36-Item Short Form Health Survey (SF-36) (from which the Short-Form Six-Dimension (SF-6D) PBM is calculated) must be modified in order to maintain relevance \[[@CR23]\].

Considering the potential issues of using generic PBMs in disability, and congenital mobility impairment specifically, it is apparent that there are a number of important considerations when using PBMs to evaluate AMT interventions and other mobility-enhancing interventions for people with congenital mobility impairments. The objective of this systematic review is therefore to examine the measurement properties of generic utility-based PBMs in various forms of congenital mobility impairment. All evidence reporting (or inferring) the validity, reliability and/or responsiveness of PBMs in conditions associated with congenital mobility impairment was collated and synthesised. Comparable condition-specific reviews of PBM performance have been conducted in mobility impairments such as rheumatoid arthritis \[[@CR24]\], CP \[[@CR25]\] and multiple sclerosis \[[@CR26]\], however PBM performance has not been systematically summarised and collated across a range of congenital mobility impairments to date.

Methods {#Sec5}
=======

This systematic review followed the University of York Centre for Reviews and Dissemination (CRD) principles for conducting searches and extracting data \[[@CR27]\]. Internet reference database searching was the main strategy for gathering evidence. Databases included: Cochrane Collaboration Register and Library, Science Direct, CINAHL, ASSIA, PsychINFO, PubMed and Web of Science. Screening of reference lists, hand-searching and targeted searching via the CRD database (which covers the Database of Abstracts of Reviews of Effects (DARE), the NHS Economic Evaluation Database (NHS EED) and the Health Technology Association (HTA) database) were carried out in addition to the primary database searches. Due to limited translation resources, only studies written or translated into English or Welsh were eligible for inclusion. Search results were managed using the online bibliographic management software Refworks (for storage of titles from the systematic searches) and Mendeley (for referencing purposes). The systematic review protocol was registered on PROSPERO (CRD42018088932).

Search terms {#Sec6}
------------

For the purpose of this review, mobility impairment was defined as any congenital (i.e. present from or shortly after birth) condition, impairment, disability or illness which causes significant restrictions to mobility for 12 months or longer, and which necessitates the use of AMT, surgery or rehabilitation to maintain, facilitate or substitute ambulation, or to reduce complications related to mobility impairment. Acquired mobility impairments (i.e. not present from birth) and short-term injuries, such as sprains or acute muscular injuries, were not included under this definition of mobility impairment.

Search terms included a mixture of MeSH (Medical Subject Heading) and non-MeSH words and phrases, divided into two groups: 'population' and 'outcomes' (see Table [1](#Tab1){ref-type="table"}). Table 1Search terms and phrasesPopulationOutcomesAssisted mobilityMobility scooter15DAssistive mobilityMobility technolog\*AQoLBrain damage\*Motor dis\*Assessment of Quality of LifeBrain injur\*Motorised scooterChild health utilitiesBuggyNeurodisabilityChild health utilityCaliperNeurological dis\*CHU9DCaneNeuromotor dis\*CHU-9DCerebral palsyNeuromuscular dis\*EQ 5DClub footOrthoti\*EQ-5DClubfootOsteogenesis imperfectaEuroQoLCrutch\*Paraly\*Health utilitiesDiplegi\*Paraplegi\*Health-utilitiesDysmeliaPhysical disab\*HUIDystroph\*Physical impair\*HUI2Electric chairPhysically disab\*HUI3Electric powered indoor outdoor chairPhysically impairedPreference basedElectric powered indoor/outdoor chairPower chairPreference-basedElectric scooterPowered chairQALYElectrically powered indoor outdoor chairPushchairQuality adjusted life yearElectrically powered indoor/outdoor chairQuadriplegi\*Quality-adjusted life yearElectronically powered indoor outdoor chairRollatorQuality of well-being scaleElectronically powered indoor/outdoor chairScooterQWB-SA\*encephal\*Spina bifidaShort Form Six DimensionEPIOCSpinal muscular atrophyShort From 6 DimensionFunctional disab\*TalipesSF6DHandicap\*Tetraplegi\*SF-6DHemiplegi\*Walk aidHydrocephalusWalk-aidKnee scooterWalkerKnee walkerWalking aidMobility aidWalking frameMobility deviceWalking stickMobility dis\*Walking-aidMobility equipmentWheelchairMobility impair\*^\*^Indicates truncated words/phrases

In order to identify studies referring to interventions rather than patient groups (e.g. studies examining 'wheelchair users' more generally), the 'population' search terms also covered relevant AMTs and mobility-enhancing interventions. The 'outcomes' search terms covered relevant PBM keywords, including specific outcome measures (such as the various versions of the EQ-5D and HUI measures). An NHS posture and mobility service manager was consulted to refine the search terms. An example of a search string is shown in Table [2](#Tab2){ref-type="table"}. Table 2Example of keyword search string("Assisted mobility" Or "Assistive mobility" Or "Brain damage\*" Or "Brain injur\*" Or Buggy Or Caliper Or Cane Or "Cerebral palsy" Or "Club foot" Or Clubfoot Or Crutch\* Or Diplegi\* Or Dysmelia Or Dystroph\* Or "Electric chair" Or "Electric powered indoor outdoor chair" Or "Electric powered indoor/outdoor chair" Or "Electric scooter" Or "Electrically powered indoor outdoor chair" Or "Electrically powered indoor/outdoor chair" Or "Electronically powered indoor outdoor chair" Or "Electronically powered indoor/outdoor chair" Or encephal\* Or EPIOC Or "Functional disab\*" Or Handicap\* Or Hemiplegi\* Or Hydrocephalus Or "Knee scooter" Or "Knee walker" Or "Mobility aid" Or "Mobility device" Or "Mobility dis\*" Or "Mobility equipment" Or "Mobility impair\*" Or "Mobility scooter" Or "Mobility technolog\*" Or "Motor dis\*" Or "Motorised scooter" Or Neurodisability Or "Neurological dis\*" Or "Neuromotor dis\*" Or "Neuromuscular dis\*" Or Orthoti\* Or "Osteogenesis imperfect" Or Paraly\* Or Paraplegi\* Or "Physical disab\*" Or "Physical impair\*" Or "Physically disab\*" Or "Physically impaired" Or "Power chair" Or "Powered chair" Or Pushchair Or Quadriplegi\* Or Rollator Or Scooter Or "Spina bifida" Or "Spinal muscular atrophy" Or Talipes Or Tetraplegi\* Or "Walk aid" Or "Walk-aid" Or Walker Or "Walking aid" Or "Walking frame" Or "Walking stick" Or "Walking-aid" Or Wheelchair) AND (15D OR AQoL OR "Assessment of Quality of Life" OR "Child health utilities" OR "Child health utility" OR CHU9D OR "CHU-9D" OR EQ. 5D OR "EQ-5D" OR EuroQoL OR "Health utilities" OR "Health-utilities" OR HUI OR HUI2 OR HUI3 OR "Preference-based" OR "Preference based" OR QALY OR "Quality adjusted life year" OR "Quality of well-being scale" OR "Quality-adjusted life year" OR "QWB-SA" OR "Short Form Six Dimension" OR "Short From 6 Dimension" OR SF6D OR "SF-6D")

Study eligibility {#Sec7}
-----------------

Any study reporting the performance of PBMs of HRQoL in patient groups with congenital mobility impairments was eligible for inclusion. This included studies reporting proxy outcomes. There was no restriction on study type. Studies focussing solely on non-PBMs of HRQoL or acquired mobility impairments were excluded. Studies which included patient groups with varying degrees of disability/disease severity were considered for inclusion if the majority of patients had a congenital mobility impairment or if the data for patients with congenital mobility impairments was reported separately (i.e. sub-group analysis).

Screening {#Sec8}
---------

Two researchers undertook each stage of the screening process. For the initial screening process, all identified studies were assessed for relevance based on their title and descriptor terms, the remaining studies were then assessed by their abstract. All studies considered relevant after the initial screening process were then obtained in full. Both reviewers screened each study independently. A third researcher was consulted when there was disagreement about the inclusion of a specific study.

Quality appraisal {#Sec9}
-----------------

All relevant studies which met the initial inclusion criteria were critically appraised for methodological quality by two researchers. Quality appraisal methods were adapted from similar systematic reviews in other clinical areas \[[@CR28]--[@CR30]\]. Quality appraisal was not used to exclude studies, but to illustrate the overall quality of research conducted in this topic area. Quality appraisal focussed on six key areas: Whether tests of statistical significance were carried outDifferences between interventions and/or patient groups (i.e. sub-group analysis)Clinical significance and relevance of resultsReporting of missing dataResponse and completion ratesExplicit reporting of inclusion/exclusion criteria

Data extraction {#Sec10}
---------------

Data extraction criteria included: Study characteristics: study type, country, number/composition of study groups, missing dataDemographics: number of participants, age, gender, type/severity of mobility impairmentMeasures: Generic PBMs used, condition-specific measures used, other clinically relevant measures usedOutcomes: Mean utility scores, mean utility scores for relevant sub-groups, statistical significance between groupsPerformance: Known group analyses, convergent validity (correlation between outcomes and/or respondent types), responsiveness, reliability, response/completion rates

Analysis of the performance of preference-based measures {#Sec11}
--------------------------------------------------------

PBM performance indicators were adapted from COSMIN measurement property guidance for health-related patient-reported outcomes \[[@CR31]\].

### Assessment of validity {#Sec12}

In this context validity refers to the extent to which a PBM can be considered to measure what it has been designed to measure (i.e. HRQoL), and whether it does so in a systematic manner. By establishing whether a specific PBM is sufficiently valid in a particular patient group, greater confidence can be placed in the generated data. We focussed predominantly on construct validity in this review.

Construct validity was assessed in a number of ways. Firstly, known-group analyses were used to assess whether specific PBMs were able to detect expected differences between different patient groups (i.e. variance due to severity of illness). Secondly, convergent validity was determined by examining correlation between comparable outcomes, for instance between PBMs and condition-specific measures with comparable constructs. Finally, convergent validity was further examined by looking at correlation between respondents types (i.e. self-reported and proxy utility outcomes). In the interest of uniformity, the strength of correlations was defined as absent (*r* \< 0.20), weak (*r* = 0.20 to 0.35), moderate (*r* = 0.35 to 0.50) and strong (*r* ≥ 0.50) \[[@CR32]\].

### Assessment of reliability {#Sec13}

Reliability refers to the replicability of results. Reliability is commonly assessed by examining test-retest results and inter-rater reliability of PBMs in defined unchanging patient groups.

### Assessment of responsiveness {#Sec14}

Responsiveness refers to the extent to which a measure can identify changes in health status \[[@CR28]\]. A responsive measure should be able to detect clinically significant changes in health outcomes over time \[[@CR29]\]. Responsiveness was determined by examining the relationship between outcomes derived from PBMs and other relevant measures, before and after an intervention.

Evidence synthesis {#Sec15}
------------------

Descriptive synthesis of search results was conducted \[[@CR27]\] and presented in tabulated form. Narrative synthesis was undertaken to develop a structured narrative of results; extracted results were grouped by type of mobility impairment and category of PBM performance.

Results {#Sec16}
=======

See Fig. [1](#Fig1){ref-type="fig"} for search outcomes and the screening process flowchart. Searches were conducted from March to May 2018. In total 1489 study articles were identified: 1332 from the bibliographic searches and 157 articles from other sources (i.e. CRD database, screening of reference lists and hand-searching), of which 410 duplicates were removed. After screening of titles and abstracts, 66 studies were identified as potentially eligible. Following full review of full-texts, 35 studies were excluded for a variety of reasons (see Fig. [1](#Fig1){ref-type="fig"}). In total 31 studies were identified as relevant and eligible for inclusion in the systematic review. Quality appraisal outcomes are presented in Table [3](#Tab3){ref-type="table"}. Fig. 1PRISMA flowchart for search outcomes and screening processTable 3Quality appraisal outcomesStudy reference (author, year)Tests of statistical significance conductedSub-group analyses conductedClinical implications discussedProportions of missing/incorrect data reportedResponse and/or completion rates reportedInclusion and/or exclusion criteria explicitly statedBartlett et al. (2010) \[[@CR33]\]**YYYYXY**Bray et al. (2017) \[[@CR15]\]**YYYYYY**Burstrom et al. (2014) \[[@CR11]\]**YYXYYX**Cavazza et al. 2016 \[[@CR34]\]**XXXXXX**Christensen et al. (2016) \[[@CR35]\]**YYYXYX**Findlay et al. (2015) \[[@CR36]\]**YYYYYX**Hendriksz etl al (2014) \[[@CR37]\].**YYYYXY**Karmur and Kulkarni (2018) \[[@CR38]\]**YXYYXX**Kennes et al. (2002) \[[@CR39]\]**YYYYXY**Kulkarni et al. (2004) \[[@CR40]\]**YXYXYY**Kulkarni (2006) \[[@CR41]\]**YYXYXY**Kulkarni et al. (2008) \[[@CR42]\]**YXYYYX**Kulkarni et al. (2008) \[[@CR43]\]**YYYXYY**Landfeldt et al. (2016) \[[@CR44]\]**YXYXYX**Lindquist et al. (2014) \[[@CR45]\]**YYYXXY**Livingston and Rosenbaum (2008) \[[@CR46]\]**YXYYXX**Lopez-Bastida et al. (2017) \[[@CR47]\]**XXYYXX**Morrow et al. (2011) \[[@CR48]\].**YYYXYY**Penner et al. (2013) \[[@CR49]\]**YYYXYX**Perez Sousa et al. (2017) \[[@CR50]\]**YYYYYY**Petrou and Kupec (2009) \[[@CR51]\]**YYYYXY**Rocque et al. (2015) \[[@CR52]\]**YYYXXY**Rosenbaum et al. (2007) \[[@CR53]\]**YYYYXY**Sims-Williams et al. (2016) \[[@CR54]\]**YYYYXY**Slaman et al. (2015) \[[@CR55]\]**YXYXXY**Tilford et al. (2005) \[[@CR56]\]**YXYXYX**Usuba et al. (2014) \[[@CR57]\]**YYYYYY**Vitale et al. (2001) \[[@CR58]\]**YYYXXY**Wallander et al. (2009) \[[@CR59]\].**YXYXYY**Young et al. (2010) \[[@CR22]\].**YYYYYY**Young et al. (2013) \[[@CR21]\]**YYYXYY**

Study and patient characteristics {#Sec17}
---------------------------------

Study and participant characteristics are presented in Table [4](#Tab4){ref-type="table"}. Most of the studies (22 of 31) were cross-sectional studies \[[@CR15], [@CR21], [@CR22], [@CR34], [@CR36]--[@CR38], [@CR40]--[@CR45], [@CR47]--[@CR52], [@CR54], [@CR58], [@CR59]\], six were prospective cohort studies \[[@CR33], [@CR35], [@CR39], [@CR46], [@CR53], [@CR57]\], two were case-control studies \[[@CR11], [@CR56]\] and one was a randomised controlled trial \[[@CR55]\]. The selected studies were conducted in a range of different countries; most were (*n* = 15) from Canada \[[@CR21], [@CR22], [@CR33], [@CR35], [@CR36], [@CR38]--[@CR43], [@CR46], [@CR49], [@CR53], [@CR57]\]. The sample sizes of relevant study groups ranged from 13 \[[@CR15]\] to 770 \[[@CR44]\]. Table 4Study characteristics and participant demographics for included studiesStudy referenceAims and objectivesCountryStudy typeCondition(s) of interestClinical and diagnostic information (% of sample)Sample sizeAge (mean ± SD; range) and gender (% of sample)Bartlett et al. (2010) \[[@CR33]\]To explore possible reasons for the observed decline in gross motor capacity of adolescents with cerebral palsy in GMFCS levels III, IV and VCanadaProspective cohortAdolescents with cerebral palsy*GMFCS level*GMFCS III: 38%GMFCS IV: 35%GMFCS V: 27%*Cerebral palsy sub-type*Diplegia: 24%Hemiplegia: 1%Tetraplegia: 71%*n* = 135Mean 14 yrs. (±2.4; range 11--17)44% female / 56% maleBray et al. (2017) \[[@CR15]\]To compare how children with mobility impairments and their parents (by proxy) report HRQoL using standard outcome measuresUKCross-sectionalChildren and adolescents with impaired mobility (relevant conditions: cerebral palsy, hemiplegia, muscular dystrophy)*Mixed diagnoses*Cerebral palsy: 85%Hemiplegia/stroke: 8%Muscular dystrophy: 8%*n* = 13Range 6-18 yrs.39% female / 62% maleBurstrom et al. (2014) \[[@CR11]\]To test the feasibility and validity of the EQ-5D-Y in a Swedish patient sample of children and adolescents with functional motor, orthopaedic and medical disabilities and to compare the results with a general population sampleSwedenCase-controlChildren and adolescents with functional motor, orthopaedic and medical disabilities (relevant conditions: artrogryposis multiple congenital, myelomeningocele, cerebral palsy, orthopaedic lower limb deformities, achondroplasia)*Mixed diagnoses*Artrogryposis multiple congenital: 14%Myelomeningocele: 17%Cerebral palsy: 20%Orthopaedic lower limb deformities: 7%Achondroplasia: 6%*n* = 71 case group*n* = 407 control group*Case group*Mean 12 yrs. (±3.1; range 7--17)61% female / 39% male*Control group*Mean 13 yrs. (±2.7; range 8--16)49% female / 51% maleCavazza et al. (2016) \[[@CR34]\]To determine the economic burden from a societal perspective and the HRQoL of patients with Duchenne muscular dystrophy, in EuropeMultinational (Bulgaria, France, Germany, Hungary, Italy, Spain, Sweden, UK)Cross-sectionalAdolescents and adults with Duchenne muscular dystrophyNot stated*n* = 268Mean age varied by country, from 11 yrs. (±5.6) in Sweden to 23 yrs. (±15.8) in Bulgaria. 70% of sample were children (range 2--17)7% female / 93% maleChristensen et al. (2016) \[[@CR35]\]To identify factors associated with a change in pain over time in children with cerebral palsyCanadaProspective cohortChildren and adolescents with cerebral palsy*GMFCS level*GMFCS I: 21%GMFCS II: 11%GMFCS III: 24%GMFCS IV: 22%GMFCS V: 22%*n* = 148Mean 8 yrs. (range 3--19)30% female / 70% maleFindlay et al. (2015) \[[@CR36]\]To explore whether HRQoL can be predicted by pain, age, GMFCS level, and sex in children with cerebral palsy and whether different pain aetiologies have varying effects on HRQoLCanadaCross-sectionalChildren with cerebral palsy*GMFCS level*GMFCS I: 26%GMFCS II: 16%GMFCS III: 23%GMFCS IV: 18%GMFCS V: 17%*Cerebral palsy sub-type*Unilateral: 19%Bilateral spastic: 75%Dyskinetic: 4%Other (ataxic and hypotonic): 2%*n* = 248Mean 10 yrs. (±4.3)37% female / 63% maleHendriksz et al. (2014) \[[@CR37]\]To assess the global burden of disease among patients with Morquio A syndrome, including impact on mobility/wheelchair use, HRQoL, pain and fatigue and the interaction between these factorsMultinational (Brazil, Colombia, Germany, Spain, Turkey, UK)Cross-sectionalChildren and adults with Morquio A syndrome*Comorbidities*Bone deformity: 75% full sampleAbnormal gait: 96% adult group / 75% child group*n* = 36 child group*n* = 27 adult group*Child group*Range 5-17 yrs. (47% aged 10--14)44% female / 56% male*Adult group*Range 18-40 yrs. (52% aged 18--24)44% female / 56% maleKarmur and Kulkarni (2018) \[[@CR38]\]To understand the quality of life of patients with myelomeningocele and shunted hydrocephalusCanadaCross-sectionalChildren and adolescents with spina bifida (myelomeningocele) and shunted hydrocephalusNot stated*n* = 131Mean 12 yrs. (±3.7)51% female / 49% maleKennes et al. (2002) \[[@CR39]\]To describe the health status of pre-adolescent children with cerebral palsy, and to determine the strength of correlations between the severity of gross motor functional impairment and other aspects of functional health status (sensory, intellectual, emotional etc.)CanadaProspective cohortChildren with cerebral palsy*GMFCS level*GMFCS I: 28%GMFCS II: 12%GMFCS III: 20%GMFCS IV: 20%GMFCS V: 21%*n* = 408Mean 8 yrs. (±1.9; range 5--15)46% female / 54% maleKulkarni et al. (2004) \[[@CR40]\]To develop and test the psychometric properties of the Hydrocephalus Outcome Questionnaire (HOQ), as a measure of health status in clinical research projects of paediatric hydrocephalusCanadaCross-sectionalChildren with hydrocephalus*Hydrocephalus aetiology*Congenital/aqueductal stenosis: 36%Myelomeningocele: 13%Other: 51%*n* = 90Mean 10 yrs. (±3.5)Gender distribution not statedKulkarni et al. (2006) \[[@CR41]\]To compare three separate methods for establishing interpretability for the HOQ, and to calculate the conversion of numerical HOQ scores into utility scores obtained from HUI2CanadaCross-sectionalChildren with hydrocephalus*Hydrocephalus aetiology*Congenital/aqueductal stenosis: 33%Myelomeningocele: 15%Intraventricular haemorrhage: 13%Other: 40%*n* = 79Mean 10 yrs. (±3.5)Gender distribution not statedKulkarni et al. (2008) \[[@CR42]\]To study the factors associated with HRQoL in Canadian children with hydrocephalus, using a comprehensive model of determinants of child health, including socioeconomic factorsCanadaCross-sectionalChildren with hydrocephalus*Hydrocephalus aetiology*Myelomeningocele: 33%Intraventricular haemorrhage of prematurity: 9%Aqueductal stenosis: 10%Post-infection: 4%Posterior fossa cyst: 5%Not stated: 39%*n* = 340Mean 11 yrs. (±3.6)Gender distribution not statedKulkarni et al. (2008) \[[@CR43]\]To investigate the feasibility and scientific properties of a child-completed version of the HOQ (cHOQ)CanadaCross-sectionalChildren with hydrocephalus*Hydrocephalus aetiology*Myelomeningocele: 34%Intraventricular haemorrhage of prematurity: 11%Aqueductal stenosis: 10%Post-infection: 4%Congenital communicating: 3%Intracranial cyst: 8%Other: 30%*n* = 273Mean 14 yrs. (±2.6)47% female / 54% maleLandfeldt et al. (2016) \[[@CR44]\]To estimate HRQoL in patients with Duchenne muscular dystrophyMultinational (Germany, Italy, UK, USA)Cross-sectionalChildren and adolescents with Duchenne muscular dystrophy*Ambulatory status*Early ambulatory (5-7 yrs): 20%Late ambulatory (8-11 yrs): 33%Early non-ambulatory (12-15 yrs): 20%Late non-ambulatory (≥16 yrs): 27%*n* = 770Mean 14 yrs. (±7.0)100% maleLindquist et al. (2014) \[[@CR45]\]To analyse quality of life in a very long-term follow-up of now adult individuals, treated for hydrocephalus (without spina bifida) during their first year of lifeSwedenCross-sectionalAdults who experienced hydrocephalus in infancy31% of study groupdiagnosed with cerebral palsy and/or epilepsy; hydrocephalus aetiologies not reported*n* = 29 study group*n* = 1613 control group*Study group*Mean 34 yrs. (range 30--41)38% female / 62% male*Control group*Matched age and gender to case groupLivingston and Rosenbaum (2008) \[[@CR46]\]To assess the stability of measurement of quality of life and HRQoL over the course of 1 year among adolescents with cerebral palsyCanadaProspective cohortAdolescents with cerebral palsy*GMFCS level*GMFCS I: 30%GMFCS II: 16%GMFCS III: 15%GMFCS IV: 25%GMFCS V: 15%*n* = 185Mean 16 yrs. (±1.75; range 13--20)47% female / 54% maleLopez-Bastida et al. (2017) \[[@CR47]\]To determine the economic burden and health-related quality of life of patients with spinal muscular atrophy and their caregivers in SpainSpainCross-sectionalChildren with spinal muscular atrophy*Spinal muscular atrophy type*Type I: 10%Type II: 74%Type III: 16%*n* = 81Mean 7 yrs. (±5.47)58% female / 42% maleMorrow et al. (2011) \[[@CR48]\]To evaluate differences between children's, parents' and doctors' perceptions of health states and HRQoL in children with chronic illness and explore factors which explain these differencesAustraliaCross-sectionalChildren with chronic conditions (relevant condition: cerebral palsy)All participants in cerebral palsy sub-group were categorised as GMFCS level V*Cerebral palsy sub-groupn* = 1 child-parent pair*n* = 1 child-doctor pair*n* = 11 parent-doctor pairs*Cerebral palsy sub-group*36% aged \> 12 yrs.Gender distribution not reportedPenner et al. (2013) \[[@CR49]\]To determine the impact of pain on activities and to identify the common physician-identified causes of pain in children and youth aged 3 to 19 years across all levels of severity of cerebral palsyCanadaCross-sectionalChildren and adolescents with cerebral palsy*GMFCS level*GMFCS I: 24%GMFCS II: 13%GMFCS III: 21%GMFCS IV: 19%GMFCS V: 23%*n* = 252Mean 9 yrs. (±4.2; range 3--19)36% female / 64% malePerez Sousa et al. (2017) \[[@CR50]\]To analyse the level of agreement between children with cerebral palsy and their parents, using the EQ-5D-Y questionnaire and its proxy versionSpainCross-sectionalChildren and adolescents with cerebral palsy*Functional classification*Grade 1 (without activity limitation): 66%Grade 2 (mild or moderate activity limitation): 34%*n* = 62Mean 10 yrs. (±2.3; range 6--17)44% female / 56% malePetrou and Kupek (2009) \[[@CR51]\]To augment previous catalogues of preference-based HRQoL weights by estimating preference-based HUI3 multiattribute utility scores associated with a wide range of childhood conditionsUKCross-sectionalChildren with childhood conditions (relevant conditions: microcephaly, cerebral palsy, spinal muscular atrophy, muscular dystrophy, spina bifida)Not stated*Relevant sub-groups*Microcephaly *n* = 40Cerebral palsy *n* = 178Muscular dystrophy or spinal muscular atrophy *n* = 45Spina bifida *n* = 42*Relevant sub-groups*Microcephaly: mean 11 yrs.Cerebral palsy: mean 11 yrs.Muscular dystrophy or spinal muscular atrophy: mean 12 yrs.Spina bifida: mean 13 yrs.Gender distribution per sub-group not reportedRocque et al. (2015) \[[@CR52]\]To characterise the quality of life of paediatric patients with spina bifida, and to analyse factors that influence HRQoL and aid in the determination of whether a correlation exists between various disease and/or personal characteristics and HRQoL scoresUSACross-sectionalChildren and adolescents with spina bifida*Underlying diagnosis*Myelomeningocele: 79%Lipomyelomeningocele: 16%Meningocele: 3%Filum terminale-related pathology: 2%Sacral agenesis: \> 1%*n* = 159Mean 12 yrs. (range 5--20)57% female / 43% maleRosenbaum et al. (2007) \[[@CR53]\]To report self- and proxy-assessed quality of life along with parental accounts of HRQoL of a cohort of adolescents with cerebral palsy participating in a longitudinal study charting mobility and self-care through the adolescent yearsCanadaProspective cohortAdolescents with cerebral palsy*GMFCS level*GMFCS I: 30%GMFCS II: 16%GMFCS III: 14%GMFCS IV: 25%GMFCS V: 16%*n* = 203Mean 16 yrs. (±1.75; range 13--20)45% female / 55% maleSims-Williams et al. (2017) \[[@CR54]\]To ascertain the quality of life of surviving children with spina bifida and to determine whether this was influenced by mobility, urinary continence, hydrocephalus, sex, family size and school attendanceUgandaCross-sectionalChildren with spina bifida45% of sample had comorbid hydrocephalus*Walking ability*Unable to walk: 47%Walk with sticks/crutches: 14%Walk unaided: 39%*n* = 66 (63 of which completed HUI3)Range 10-14 yrs.44% female / 56% maleSlaman et al. (2015) \[[@CR55]\]To evaluate the cost-utility of a lifestyle interventions among adolescents and young adults with cerebral palsyThe NetherlandsRandomised controlled trial (single-blind)Adolescents and young adults with cerebral palsyIntervention group GMFCS levelGMFCS I: 61%GMFCS II: 32%GMFCS III: 7%GMFCS IV: 0%Control group GMFCS levelGMFCS I: 55%GMFCS II: 31%GMFCS III: 10%GMFCS IV: 4%*n* = 20 intervention group*n* = 20 control group*Intervention group*Mean 20 yrs. (±3.0)57% female / 43% male*Control group*Mean 20 yrs. (±3.0)48% female / 52% maleTilford et al. (2005) \[[@CR56]\]To provide information on the preference scores of children with spina bifida aperta and to measure the impact of caring for a child with spina bifida consistent with economic evaluationsUSACase-controlChildren with spina bifida*Case group lesion level*Sacral: 42%Lower lumbar: 34%Thoracic: 25%*n* = 80 case group*n* = 30 general population control group*Case group*Mean 9 yrs. (±4.6)61% female / 39% male*General population control group*Mean 7 yrs. (±4.0)55% female / 45% maleUsuba et al. (2014) \[[@CR57]\]To explore the magnitude and timing of changes in gross motor function and HRQoL among persons with cerebral palsy over an 8-year period, with specific interest in comparing those who made the transition to adult servicesCanadaProspective cohortAdolescents and adults with cerebral palsy*GMFCS level (full sample)*GMFCS I: 22%GMFCS II: 13%GMFCS III: 13%GMFCS IV: 22%GMFCS V: 30%*n* = 31 'younger adults' group*n* = 23 'older adults' group*'Younger adults' group*Mean 15 yrs. (range 13--17)*'Older adults' group*Mean 26 yrs. (range 23--32)*Full sample*46% female / 54% maleVitale et al. (2001) \[[@CR58]\]To examine whether the SF-36 and EQ-5D would be useful for evaluating quality of life in adolescents with orthopaedic conditionsUSACross-sectionalAdolescents with orthopaedic problems (relevant condition: cerebral palsy)Not stated*n* = 14 cerebral palsy sub-groupCerebral palsy sub-group age data not reported (full sample: mean 14 yrs. \[range 10--18\])Gender distribution not reportedWallander et al. (2009) \[[@CR59]\]To review a group of patients over 60 years of age who had been treated for congenital talipes equinus varus (CTEV) in infancy, using generic instruments for the assessment of quality of life in general and a specific foot and ankle instrument for assessment of functionSwedenCross-sectionalAdults treated for CTEV in infancy*Clubfoot laterality*Unilateral: 54%Bilateral: 46%*n* = 83Mean 64 yrs. (range 62--67)24% female / 76% maleYoung et al. (2010) \[[@CR22]\]To describe the health and quality of life outcomes of youth and young adults with cerebral palsy, and to explore the impact of 3 factors (cerebral palsy severity, age and sex) on quality of life outcomesCanadaCross-sectionalAdolescents and young adults with cerebral palsy*'Youth' group GMFCS level*GMFCS I: 22%GMFCS II: 12%GMFCS III: 18%GMFCS IV: 25%GMFCS V: 22%*'Adult' group GMFCS level*GMFCS I: 23%GMFCS II: 14%GMFCS III: 19%GMFCS IV: 25%GMFCS V: 20%*n* = 129 'youth' group*n* = 70 'adult' group*'Youth' group*Mean 15 yrs. (±1.36)45% female / 55% male*'Adult' group*Mean 26 yrs. (±2.63)40% female / 60% maleYoung et al. (2013) \[[@CR21]\]To describe the health and HRQoL outcomes of youths and young adults with spina bifidaCanadaCross-sectionalAdolescents and young adults with spina bifida*'Youth' group lesion level*Thoracic: 25%High-lumbar: 18%Low-lumbar: 30%Sacral: 28%*'Adult' group lesion level*Thoracic: 15%High-lumbar: 23%Low-lumbar: 31%Sacral: 15%Unknown: 15%*n* = 40 'youth' group*n* = 13 'adult' group*'Youth' group*Mean 16 yrs. (±1.3; range 13--17)65% female / 35% male*'Adult' group*Mean 26 yrs. (±3.10; range 23--32)77% female / 23% male

Fourteen studies included data relating to CP \[[@CR22], [@CR33], [@CR35], [@CR36], [@CR39], [@CR46], [@CR48]--[@CR51], [@CR53], [@CR55], [@CR57], [@CR58]\], six included data relating to SB \[[@CR21], [@CR38], [@CR51], [@CR52], [@CR54], [@CR56]\] and five included data relating to childhood hydrocephalus \[[@CR40]--[@CR43], [@CR45]\]. Data for a range of other relevant conditions were also found in either single studies or from extractable sub-groups, these included muscular dystrophy \[[@CR34], [@CR44]\], spinal muscular atrophy \[[@CR47]\], Morquio A syndrome \[[@CR37]\], congenital clubfoot \[[@CR59]\] and microcephaly \[[@CR51]\]. Three studies focused on multiple conditions where sub-group data could not be examined separately \[[@CR11], [@CR15], [@CR51]\].

The vast majority of studies (23 of 31) included only child/adolescent participants \[[@CR11], [@CR15], [@CR33], [@CR35], [@CR36], [@CR38]--[@CR44], [@CR46]--[@CR54], [@CR56], [@CR58]\]. Of the remaining studies, six included children/adolescents and adults \[[@CR21], [@CR22], [@CR34], [@CR37], [@CR55], [@CR57]\] and two included only adults \[[@CR45], [@CR59]\]. PBM reporting was predominantly from proxies (13 of 23 studies); eleven studies included both self-reported and proxy data \[[@CR15], [@CR21], [@CR22], [@CR36], [@CR43], [@CR48]--[@CR50], [@CR53], [@CR54], [@CR57]\] and seven studies included only self-reported PBM data \[[@CR11], [@CR34], [@CR37], [@CR45], [@CR55], [@CR58], [@CR59]\].

In terms of use of PBMs, 22 of the studies used a version of the HUI \[[@CR15], [@CR21], [@CR22], [@CR33], [@CR35], [@CR36], [@CR38]--[@CR44], [@CR46], [@CR48], [@CR49], [@CR51]--[@CR54], [@CR56], [@CR57]\], eight used a version of the EQ-5D \[[@CR11], [@CR15], [@CR34], [@CR37], [@CR47], [@CR50], [@CR58], [@CR59]\], three used a version of AQoL instrument \[[@CR21], [@CR22], [@CR57]\], one used the 15D \[[@CR45]\] and one used the SF-6D \[[@CR55]\].

Narrative synthesis {#Sec18}
-------------------

Utility outcomes are presented in Table [5](#Tab5){ref-type="table"} and PBM performance outcomes are presented in Table [6](#Tab6){ref-type="table"}. The narrative synthesis is categorised by type of mobility impairment and PBM performance indicator. No studies reported PBM reliability outcomes, therefore reliability results have not been presented. Table 5Summary of utility outcomes for included studiesStudy referenceCondition(s) of interestRespondent typePBM (s)Other relevant outcome measuresOverall utility scores (mean ± SD)Sub-group utility scores (mean ± SD)Bartlett et al. (2010) \[[@CR33]\]Adolescents with cerebral palsyProxy (parent)HUI3Gross Motor Function Measure 66 Items (GMFM-66)Spinal Alignment and Range of Motion Measure (SAROMM)NAOverall utility scores not reported, only vision, cognition and pain dimensions used - ambulation, hearing, speech, dexterity and emotion dimensions all excluded due to conceptual overlap with other measuresNABray et al. (2017) \[[@CR15]\]Children and adolescents with impaired mobility (relevant conditions: cerebral palsy, hemiplegia, muscular dystrophy)Self-reported and proxy (parent); matched-pairsHUI2, HUI3 and EQ-5D-YVisual analogue scale (VAS)*Child self-reported*HUI2: 0.53 (±0.07)HUI3: 0.22 (±0.09)EQ-5D-Y: 0.24 (±0.30)*Parent proxy*HUI2: 0.49 (±0.09)HUI3: 0.16 (±0.10)EQ-5D-Y: 0.01 (±0.14)NABurstrom et al. (2014) \[[@CR11]\]Children and adolescents with functional motor, orthopaedic and medical disabilities (relevant conditions: artrogryposis multiple congenital, myelomeningocele, cerebral palsy, orthopaedic lower limb deformities, achondroplasia)Self-reportedEQ-5D-YVASKIDSCREEN-27KIDSCREEN-10Self-rated health (SRH)Life satisfaction ladder (LSL)NAOverall utility scores not reported, only dimension scores reportedNACavazza et al. (2016) \[[@CR34]\]Adolescents and adults with Duchenne muscular dystrophySelf-reportedEQ-5D-YVASBarthel IndexMean 0.24Varied by country, ranging from − 0.71 (±0.41) in Sweden to 0.66 (±0.08) in BulgariaNAChristensen et al. (2016) \[[@CR35]\]Children and adolescents with cerebral palsyProxy (caregiver)HUI3Wong-Baker FACES Pain Rating ScaleNAOverall utility scores not reported, only HUI3 pain dimension measuredNAFindlay et al. (2015) \[[@CR36]\]Children with cerebral palsySelf-reported and proxy (caregiver); proportion of proxy data not reportedHUI3DISABKIDS Chronic Generic module (DCGM-37)DISABKIDS Smiley measure (DSM)Wong-Baker FACES Pain Rating ScaleNAOverall utility scores not reported, only HUI3 pain dimension measuredNAHendriksz et al. (2014) \[[@CR37]\]Children and adults with Morquio A syndromeSelf-reportedEQ-5D-5 LBrief Pain Inventory Short Form (BPI-SF)Adolescent Pediatric Pain Tool (APPT)NAOverall utility scores not reported*Child group: utility score by wheelchair use frequency*No use: 0.534Occasional use: 0.664Full-time use: − 0.180*Adult group: utility score by wheelchair use frequency*No use: 0.846Occasional use: 0.582Full-time use: 0.057Karmur and Kulkarni (2018) \[[@CR38]\]Children and adolescents with spina bifida (myelomeningocele) and shunted hydrocephalusProxy (caregiver)HUI2 and HUI3 (version used to calculate utility scores not stated)Hydrocephalus Outcome Questionnaire (HOQ)0.51 (±0.28)NAKennes et al. (2002) \[[@CR39]\]Children with cerebral palsyProxy (caregiver)HUI3Functional Independence Measure for Children (WeeFIM)Strength and Difficulties Questionnaire (SDQ)Wide Range Achievement Test (WRAT)NAOverall utility scores not reported, only dimension scores reportedNAKulkarni et al. (2004) \[[@CR40]\]Children with hydrocephalusProxy (parent)HUI2HOQNAOverall utility scores not reportedNAKulkarni et al. (2006) \[[@CR41]\]Children with hydrocephalusProxy (parent)HUI2HOQNAOverall utility scores not reportedNAKulkarni et al. (2008) \[[@CR42]\]Children with hydrocephalusProxy (caregiver)HUI3HOQ0.58 (±0.32)NAKulkarni et al. (2008) \[[@CR43]\]Children with hydrocephalusSelf-reported and proxy (caregiver); proxy-reported HUI3 and HOQ, self-reported cHOQHUI3Child-completed version of the HOQ (cHOQ)0.71 (±0.27)NALandfeldt et al. (2016) \[[@CR44]\]Children and adolescents with Duchenne muscular dystrophyProxy (caregiver); although patients included in data collection, only proxy utility data reportedHUI (version not stated)Pediatric Quality of Life Inventory (PedsQL) neuromuscular module 3.0NAOverall utility scores not reported*Utility score by ambulatory status*Early ambulatory: 0.75Late non-ambulatory: 0.15Lindquist et al. (2014) \[[@CR45]\]Adults who experienced hydrocephalus in infancySelf-reported15DNAStudy group: 0.92Control group: 0.95Livingston and Rosenbaum (2008) \[[@CR46]\]Adolescents with cerebral palsyProxy (parent)HUI3Quality of Life Instrument for People with Developmental Disabilities (QOL Instrument)NAOverall utility scores not reportedNALopez-Bastida et al. (2017) \[[@CR47]\]Children with spinal muscular atrophyProxy (caregiver)EQ-5D-3 LVASBarthel Index0.16 (±0.44)*Utility score by spinal muscular atrophy type*Type II spinal muscular atrophy sub-group: − 0.01 (±0.35)Scores for Type I and III not reportedMorrow et al. (2011) \[[@CR48]\]Children with chronic conditions (relevant condition: cerebral palsy)Self-reported and proxy (parent and doctor); matched groupsHUI2 and HUI3NANAOverall utility scores not reported for relevant sub-groupNAPenner et al. (2013) \[[@CR49]\]Children and adolescents with cerebral palsySelf-reported and proxy (parent and physician); proxy-reported HUI3 pain score, self-reported Wong-Baker FACES Pain ScaleHUI3Wong-Baker FACES Pain Rating ScaleNAOverall utility scores not reported, only HUI3 pain dimension measuredNAPerez Sousa et al. (2017) \[[@CR50]\]Children and adolescents with cerebral palsySelf-reported and proxy (mother and father); matched groupsEQ-5D-YVASNAOverall utility scores not reported, only dimension scores reportedNAPetrou and Kupek (2009) \[[@CR51]\]Children with childhood conditions (relevant conditions: microcephaly, cerebral palsy, spinal muscular atrophy, muscular dystrophy, spina bifida)Proxy (caregiver)HUI3NA*Mean utility by condition*Microcephaly: 0.141Cerebral palsy: 0.276Muscular dystrophy or spinal muscular atrophy: 0.386Spina bifida: 0.452NARocque et al. (2015) \[[@CR52]\]Children and adolescents with spina bifidaSelf-reported and proxy (caregiver); predominantly proxy (11% self-reported)HUI3NANAOverall utility scores not reported*Utility score by type of spina bifida*Myelomeningocele: 0.51Closed spinal dysraphism: 0.77*Utility score by treatment history*No history of shunt or CM-II decompression: 0.74Shunt but no CM-II decompression: 0.49Shunt and CM-II decompression: 0.29Rosenbaum et al. (2007) \[[@CR53]\]Adolescents with cerebral palsySelf-reported and proxy (parent); proxy-reported HUI3, 34% self-reported QOL InstrumentHUI3QOL Instrument0.42 (±0.41)*Utility score by GMFCS level*GMFCS I: 0.84 (±0.20)GMFCS II: 0.50 (±0.31)GMFCS III: 0.39 (±0.31)GMFCS IV: 0.16 (±0.26)GMFCS V: − 0.08 (±0.23)Sims-Williams et al. (2017) \[[@CR54]\]Children with spina bifidaSelf-reported and proxy (caregiver); matched pairsHUI3VAS*Child self-reported*0.58 (95% CI 0.49--0.66)*Caregiver proxy*0.55 (95% CI 0.47--0.63)NASlaman et al. (2015) \[[@CR55]\]Adolescents and young adults with cerebral palsySelf-reportedSF-6D36-Item Short Form Survey (SF-36) - SF-6D utility outcomes derived from SF-36*Baseline*Control: 0.74 (±0.12)Intervention: 0.75 (±0.10)*6 months post intervention*Control: 0.77 (±0.12)Intervention: 0.80 (±0.03)NATilford et al. (2005) \[[@CR56]\]Children with spina bifidaProxy (caregiver)HUI2Quality of Well-Being scale (QWB)Case group: 0.55 (±0.24)*Utility by case group lesion level*Sacral lesion: 0.61 (±0.26)Lower lumbar lesion: 0.54 (±0.19)Thoracic lesion: 0.45 (±0.25)General population control group: 0.93 (±0.11)Usuba et al. (2014) \[[@CR57]\]Adolescents and adults with cerebral palsySelf-reported and proxy (undefined); predominantly proxy (40% self-reported)HUI3 and AQoLSRH*Baseline (both groups)*HUI3: 0.29 (±0.39)AQoL: 0.35 (±0.33)*8-year follow-up (both groups)*HUI3: 0.29 (±0.38)AQoL: 0.35 (±0.32)NAVitale et al. (2001) \[[@CR58]\]Adolescents with orthopaedic problems (relevant condition: cerebral palsy)Self-reportedEQ-5D (version not stated)SF-36Cerebral palsy sub-group: 0.922NAWallander et al. (2009) \[[@CR59]\]Adults treated for CTEV in infancySelf-reportedEQ-5D (version not stated)SF-36VASAmerican Academy of Orthopaedic Surgeons Foot and Ankle QuestionnaireNAOverall utility scores not reportedNAYoung et al. (2010) \[[@CR22]\]Adolescents and young adults with cerebral palsySelf-reported and proxy (caregiver); predominantly self-reported (45% proxy)HUI3 and AQoLSRHHealth Assessment Questionnaire (HAQ)Combined age groupsHUI3: 0.30 (±0.42)AQoL: 0.28 (±0.33)*Utility score by age group (HUI3 / AQoL)*'Youth' group: 0.30 (±0.43) / 0.28 (±0.34)'Adult' group: 0.31 (±0.40) / 0.28 (±0.314)*Youth group: utility score by GMFCS level (HUI3 / AQoL)*GMFCS I: 0.67 (±0.32) / 0.58 (±0.31)GMFCS II: 0.59 (±0.35) / 0.53 (±0.34)GMFCS III: 0.43 (±0.39) / 0.31 (±0.32)GMFCS IV: 0.08 (±0.25) / 0.06 (±0.12)GMFCS V: − 0.13 (±0.19) / 0.01 (±0.07)*Adult group: utility score by GMFCS level (HUI3 / AQoL)*GMFCS I: 0.64 (±0.30) / 0.52 (±0.32)GMFCS II: 0.50 (±0.39) / 0.33 (±0.24)GMFCS III: 0.53 (±0.27) / 0.39 (±0.27)GMFCS IV: 0.06 (±0.21) / 0.10 (±0.20)GMFCS V: − 0.14 (±0.20) / 0.02 (±0.06)Young et al. (2013) \[[@CR21]\]Adolescents and young adults with spina bifidaSelf-reported and proxy (caregiver); predominantly self-reported (15% proxy)HUI3 and AQoLSRHHAQCombined age groupsHUI3: 0.52 (±0.28)AQoL: 0.34 (±0.24)*Utility score by age group (HUI3 / AQoL)*'Youth' group: 0.58 (±0.27) / 0.37 (±0.26)'Adult' group: 0.36 (±0.27) / 0.25 (±0.17)*Utility score by lesion level (HUI3 / AQoL)*Thoracic: 0.29 (±0.14) / 0.22 (±0.14)High-lumbar: 0.44 (±0.31) / 0.28 (±0.23)Low-lumbar: 0.63 (±0.23) / 0.39 (±0.21)Sacral: 0.76 (±0.20) / 0.51 (±0.33)Unknown: 0.22 (±0.02) / 0.09 (±0.04)Table 6Summary of PBM performance for included studiesStudy referenceCondition(s) of interestKnown-group analysesConstruct validity: comparing outcomesConstruct validity: comparing PBMsConstruct validity: comparing respondentsResponsivenessBartlett et al. (2010) \[[@CR33]\]Adolescents with cerebral palsyHUI3 vision, cognition and pain dimensions steadily declined as GMFCS level increased, statistical significance not reported.Examining correlation coefficients, there was no indication that the HUI3 vision (*r =* 0.01; *p* = 0.92), cognition (*r =* − 0.05; *p* = 0.59) or pain dimensions (*r =* 0.16; *p* = 0.07) were determinants of motor capacity, as measured using the GMFM-66.NANAIndividuals with a GMFCS level of V exhibited the largest mean decreases in HUI3 dimension levels over time, ranging from − 0.2 (±1.2) for the HUI3 vision dimension to − 0.3 (±1.3) for the HUI3 cognition and pain dimensions.Bray et al. (2017) \[[@CR15]\]Children and adolescents with impaired mobility (relevant conditions: cerebral palsy, hemiplegia, muscular dystrophy)NANALarge variance between mean utility scores derived from different PBMs, ranging from 0.24 (EQ-5D-Y) to 0.53 (HUI2) for child self-reported utility, and from 0.01 (EQ-5D-Y) to 0.49 (HUI2) for parent-reported proxy utility.A significant respondent type effect was found, with mean child self-reported utility scores significantly (*p* ≤ 0.021) higher than equivalent proxies on all PBMs.Significant strong correlations were found between utility scores for children/parent proxies using all measures: EQ-5D-Y (*r =* 0.67; *p* = 0.026), HUI2 (*r =* 0.73; *p* = 0.005) and HUI3 (*r =* 0.84; *p* \< 0.001).Using Bland-Altman plots, sufficient agreement between utility scores for children/parent proxies was found for the HUI2 (CL = 0.22) and HUI3 (CL = 0.22). EQ-5D-Y exhibited clinically important discrepancies between child and parent proxy responses (CL = 1.04).NABurstrom et al. (2014) \[[@CR11]\]Children and adolescents with functional motor, orthopaedic and medical disabilities (relevant conditions: artrogryposis multiple congenital, myelomeningocele, cerebral palsy, orthopaedic lower limb deformities, achondroplasia)Statistically significant (*p* ≤ 0.001) differences between case and control groups on all dimensions. Mean dimension scores not reported, proportions of patients choosing each dimension level indicate case group reported more problems on all dimensions than the control group: 83% of case group reported some/a lot of problems on any dimension, compared to 37% of control group; likewise 21% of case group reported extreme problems on any dimension, compared to 2% of control group.Strong significant correlation was found between the EQ-5D-Y anxiety/depression dimension and the KIDSCREEN-27 psychological well-being dimension (*r =* − 0.51; *p* = 0.001); KIDSCREEN-27 physical well-being dimension (*r =* − 0.53; *p* = 0.001); and life satisfaction ladder (LSL) (*r =* − 0.54; *p* \< 0.001). Moderate correlation also found between this dimension and the KIDSCREEN-10 HRQoL index score (*r =* − 0.50; *p* = 0.001) and self-reported health (SRH) (0.42; *p* = 0.007).The self-care EQ-5D-Y dimension exhibited moderate correlation with the KIDSCREEN-27 physical wellbeing dimension (*r =* − 0.37; *p* = 0.028) and the usual activities EQ-5D-Y dimension was moderately correlated with the KIDSCREEN-27 psychological wellbeing dimension (*r =* − 0.35; *p* = 0.027). All other correlations were weak or absent.NANANACavazza et al. (2016) \[[@CR34]\]Adolescents and adults with Duchenne muscular dystrophyNANANANANAChristensen et al. (2016) \[[@CR35]\]Children and adolescents with cerebral palsyNAUsing multivariate linear regression, a significant association was found between the HUI3 pain dimension score at baseline and GMFCS level (b = − 0.11, β = − 0.15; *p* \< 0.036; 95% CI − 0.21 to − 0.01): higher pain score at baseline was associated with greater improvement in pain status in GMFCS level I compared to level V.NANAUsing one-way ANOVA analysis, a significant association was found between physician primary pain aetiology and change in HUI3 pain status (*p* = 0.001): children with musculoskeletal pain at baseline showed significant improvements (mean change 0.55; 95% CI 0.053 to 1.05) compared to children without pain at baseline (mean change − 0.39; 95% CI − 0.62 to − 0.15) (p = 0.006). No other associations were reported. HUI3 pain dimension scores did not change significantly over time: median score of 2 (out of 5) at both visits. However, 55% of children changed pain status over time: 34% worsening, 21% improving.Findlay et al. (2015) \[[@CR36]\]Children with cerebral palsyNANANANANAHendriksz et al. (2014) \[[@CR37]\]Children and adults with Morquio A syndromeA significant effect of wheelchair use on utility outcomes was reported; significant differences reported between: adult non-wheelchair users and occasional wheelchair users (*p* = 0.0115); adult occasional wheelchair users and full-time wheelchair users (*p* = 0.0007); child occasional wheelchair users and full-time wheelchair users (p = 0.0018); and child non-wheelchair users and full-time wheelchair users (*p* = 0.0018). Children who occasionally used a wheelchair had a higher mean utility score on average than non-wheelchair users, although both groups had higher average utility scores than full-time wheelchair users.NANANANAKarmur and Kulkarni (2018) \[[@CR38]\]Children and adolescents with spina bifida (myelomeningocele) and shunted hydrocephalusUsing multivariate regression analysis, anatomical level of myelomeningocele had a significant effect on utility score (*p* = 0.01): lower anatomical level of myelomeningocele was associated with a higher utility score.NANANANAKennes et al. (2002) \[[@CR39]\]Children with cerebral palsyNAUsing Kendall's tau-b test of association, the HUI3 dimension most associated with GMFCS level was ambulation (tau-b = 0.82; *p* \< 0.01): higher GMFCS level was associated with increased mobility impairment.Moderate correlations (ranging from tau-b = 0.36 to 0.58; *p* \< 0.01) were found between GMFCS level and the vision, speech and dexterity dimensions. Overall patterns were similar to the ambulation dimension, but correlations were weaker.Hearing (tau-b = 0.16; *p* = 0.04) and cognition (tau-b = 0.27; *p* \< 0.01) dimensions had statistically significant but low association with GMFCS level. The emotion (tau-b = 0.03; *p* = 0.24) and pain (tau-b = 0.07; *p* = 0.37) dimensions were not significantly associated with GMFCS level.NANANAKulkarni et al. (2004) \[[@CR40]\]Children with hydrocephalusNAStrong correlation was found between utility score and the HOQ overall health (*r =* 0.81), physical health (*r =* 0.88), social-emotional (*r =* 0.56) and cognitive (*r =* 0.57) scores.NANANAKulkarni et al. (2006) \[[@CR41]\]Children with hydrocephalusNACorrelation between utility score and HOQ overall health score was high (*r =* 0.81), a scatterplot demonstrated a strong linear relationship. Simple and complex linear regression models both accounted for a large proportion of HUI2 variability (adjusted R^2^ = 0.66 and 0.80 respectively).NANANAKulkarni et al. (2008) \[[@CR42]\]Children with hydrocephalusNAMean utility score (0.58 ± 0.63) close to cHOQ mean scores for overall health (0.65 ± 0.20), Physical health (0.66 ± 0.25), Cognitive health (0.55 ± 0.28) and Social-emotional health (0.71 ± 0.19). Statistical significance not reported.NANANAKulkarni et al. (2008) \[[@CR43]\]Children with hydrocephalusNASignificant correlation was found between the cHOQ overall health score (self-reported) and utility score (proxy-reported) (*r =* 0.60; *p* \< 0.001).NANANALandfeldt et al. (2016) \[[@CR44]\]Children and adolescents with Duchenne muscular dystrophyAmbulatory class was significantly associated with proxy-reported utility scores (*p* \< 0.001), decreasing from early ambulatory class (mean 0.75) to late non-ambulatory class (mean 0.15). Caregiver assessments of health and mental status were significantly associated with utility score (*p* \< 0.001).NANANANALindquist et al. (2014) \[[@CR45]\]Adults who experienced hydrocephalus in infancyThe study group had significantly (*p* ≤ 0.004) lower dimension scores compared to the control group in vision, eating, usual activities, mental function dimensions. The most reported problems were associated with the neuroimpairment subgroup (mean utility score 0.87 compared to 0.94 in the no neuroimpairment subgroup). The subgroup without neuroimpairment were not significantly different to the control in terms of mean utility score (0.94 and 0.95 respectively, p value not reported).NANANANALivingston and Rosenbaum (2008) \[[@CR46]\]Adolescents with cerebral palsyNADisattenuated correlation coefficients between utility scores and QOL Instrument scores demonstrated weak to moderate correlation for the being (*r =* 0.48); belonging (*r =* 0.35); becoming (*r =* 0.29) and overall quality of life (*r =* 0.35) scales. The two measure shared up to 23% variance.NANAGeneralizability coefficients were calculated to assess variability of scores over time. Dimensions with greater stability (i.e. larger G scores) had less variability between individuals over time. The ambulation dimension (G = 0.94) and overall utility (G = 0.91) were found to be highly stable; while the speech (G = 0.87), vision (G = 0.87); dexterity (G = 0.82), cognition (G = 0.81), and hearing (G = 0.72) dimensions were moderately stable. The pain (G = 0.48) and emotion (G = 0.24) dimensions were found to have low stability.Lopez-Bastida et al. (2017) \[[@CR47]\]Children with spinal muscular atrophyChildren with Type II spinal muscular atrophy were found to have a lower average utility score (− 0.012) than the combined average of children with all types of spinal muscular atrophy (0.158). Statistical significance was not reported.NANANANAMorrow et al. (2011) \[[@CR48]\]Children with chronic conditions (relevant condition: cerebral palsy)NANANAAgreement between respondents was assessed using Cohen's kappa coefficient. Moderate agreement was found between parents of children with cerebral palsy and doctors for the HUI2 dimensions of sensation (63.6% agreement; Kappa 0.41), cognition (70%; Kappa 0.56) and self-care (100%; Kappa 1). Only the HUI3 ambulation dimension (63.6%; Kappa 0.46) demonstrated moderate agreement. All other dimensions exhibited slight or fair agreementNAPenner et al. (2013) \[[@CR49]\]Children and adolescents with cerebral palsyA significant negative correlation was found between the HUI3 pain dimension and GMFCS level (*r =* 0.36; *p* \< 0.001).NAGood correlation was found between child self-reported pain (Wong-Baker scale) and proxy reported pain (HUI3 pain dimension) (Goodman and Kruskall's y = 0.57; *p* \< 0.001). Using the HUI3 pain dimension, physicians identified pain in 4.4% of cases where parent proxies did not identify pain. In 17.4% of cases, parent proxies identified pain when physicians did not. Statistical significance not reported.NAPerez Sousa et al. (2017) \[[@CR50]\]Children and adolescents with cerebral palsyNANANAChild/father agreement was poor for all EQ-5D-Y dimensions (Kappa range 0.016--0.067; non-significant). Child/mother agreement between dimensions was mostly poor (Kappa range 0.057--0.389; non-significant), however for the mobility dimensions agreement was good (Kappa 0.713; *p* = 0.000) and for the usual activities dimension agreement was moderate (Kappa 0.436; *p* = 0.000). Mothers and father both tended to report fewer problems (by proxy) than the child.NAPetrou and Kupek (2009) \[[@CR51]\]Children with childhood conditions (relevant conditions: microcephaly, cerebral palsy, spinal muscular atrophy, muscular dystrophy, spina bifida)Microcephaly: Adjusted disutility from perfect health was estimated to be − 0.820 (95% CI − 0.670 to − 0.970). Adjusted disutility from childhood norms was estimated to be − 0.745 (95% CI − 0.598 to − 0.899).Cerebral palsy: Adjusted disutility from perfect health was estimated to be − 0.726 (95% CI − 0.607 to − 0.846). Adjusted disutility from childhood norms was estimated to be − 0.652 (95% CI − 0.536 to − 0.775).Muscular dystrophy and spinal muscular atrophy: Adjusted disutility from perfect health was estimated to be − 0.616 (95% CI − 0.471 to − 0.761). Adjusted disutility from childhood norms was estimated to be − 0.541 (95% CI − 0.400 to − 0.690).Spina bifida: Adjusted disutility from perfect health was estimated to be − 0.552 (95% CI − 0.404 to − 0.701). Adjusted disutility from childhood norms was estimated to be − 0.478 (95% CI − 0.333 to − 0.630).NANANANARocque et al. (2015) \[[@CR52]\]Children and adolescents with spina bifidaDiagnosis and type of spina bifida had a significant effect on overall utility and certain dimension scores. Overall utility was found to be significantly lower (*p* \< 0.001) in children and adolescents with myelomeningocele compared to individuals with closed dysraphism. The HUI3 ambulation dimension was significantly lower (*p* \< 0.001) in individuals with open myelomeningocele compared to individuals with closed neural tube defects. The HUI3 cognition dimension was significantly lower (*p* = 0.039) in individuals with open myelomeningocele compared to individuals with closed neural tube defectsUtility and ambulation scores were significantly associated with bowel/bladder continence (*p* \< 0.05). Those with bowel continence had higher average utility scores.Utility scores were significantly lower for patients with a history of receiving shunt and/or CM-II decompression interventions (*p* \< 0.005). The dimensions of cognition (*p* = 0.17) and ambulation (p = 0.002) were found to be significantly lower for individuals with a history of shunting, while the dimensions of speech (*p* = 0.01) and cognition (*p* = 0.005) were significantly lower for individuals with a history of CM-II decompression. The results remained significant when controlled for age; shunt status accounted for 10.5% of variability in overall utility scores. Shunt revision status weakly correlated with utility score (*r =* − 0.197; *p* = 0.048) and dimension scores for vision, speech, ambulation (coefficients not given; p values ranged from 0.01 to 0.05).NANANANARosenbaum et al. (2007) \[[@CR53]\]Adolescents with cerebral palsyGMFCS level was found to have a significant impact on utility score (*p* \< 0.01); average utility scores decreased steadily as GMFCS level increased. Post-hoc Bonferoni correction confirmed significant differences in mean overall utility scores between all GMFCS levels (p values not reported), except between levels II and III (*p* = 0.82). HUI3 dimension levels were also significantly associated with GMFCS level for all dimensions (*p* \< 0.05).A strong negative correlation was found between utility score and GMFCS level (*r =* − 0.81; p value not reported)Adolescents' ability to self-report using the QOL Instrument was significantly associated (*p* \< 0.01) with parent-reported HUI3 ratings of speech (tau-b = 0.52); cognition (tau-b = 0.50); dexterity (tau-b = 0.35); ambulation (tau-b = 0.31); vision (tau-b = 0.22) and hearing (tau-b = 0.19).Utility score was significantly (p value not reported) but weakly correlated with scores on the QOL Instrument for Being (*r =* 0.37), Belonging (*r =* 0.17), Becoming (*r =* 0.20), and Overall quality of life (*r =* 0.28). Utility scores explained between 2.9% (Belonging) and 14% (Being) of variance in QOL Instrument scores.NANANASims-Williams et al. (2016) \[[@CR54]\]Children with spina bifidaModerate correlation was found between child-reported (*r =* 0.49) and proxy-reported (*r =* 0.38) utility scores and child-reported VAS - the authors describe this as a 'poor' correlation, p values not reported.NAChild self-reported and caregiver proxy utility scores were highly correlated (*r =* 0.85; p value not reported).NASlaman et al. (2015) \[[@CR55]\]Adolescents and young adults with cerebral palsyNANANANANo significant difference between the control and intervention groups at the end of the trial (*p* = 0.42). QALYs gained equated to 0.78 for the control group, and 0.79 for the intervention group; the incremental difference of 0.013 was not significant (*p* = 0.76)Tilford et al. (2005) \[[@CR56]\]Children with spina bifidaA Trend test across the case group revealed that lesion level had a significant effect (at *p* = 0.01 level) on average utility score, with individuals with thoracic lesions scoring the lowest utility scores on average.NANANANAUsuba et al. (2014) \[[@CR57]\]Adolescents and adults with cerebral palsyNANAAverage utility scores varied depending on PBM used; HUI3 derived utility scores were lower at baseline (0.29) and 8-year follow-up (0.29) than equivalent AQoL derived utility scores (0.35 and 0.32 respectively); statistical significance not reported.NAThe 'older adult' group were more likely to report utility deterioration than the 'younger adult' group (HUI3: Relative risk \[RR\] = 1.19; 95% CI 0.66--2.15 / AQoL: RR *=* 3.17; 95% CI 1.12--9.00).A significant interaction was found between age group and time of survey using the AQoL (*p* = 0.002); AQoL derived utility improved over time in the 'younger adult' group but the opposite occurred in the 'older adult' group.The distribution of PBM dimension scores was stable across the 8-year follow-up, except for the AQoL social relationships, AQoL independent living and HUI3 ambulation dimensions, which all improved in the 'younger adult' group but deteriorated in 'older adult' group.Vitale et al. (2001) \[[@CR58]\]Adolescents with orthopaedic problems (relevant condition: cerebral palsy)There was found to be a significant difference (*p* \> 0.05) between the mean utility scores of children with cerebral palsy (mean 0.92) and children with scoliosis with comorbidities (mean 0.725), but not children with idiopathic scoliosis (mean 0.889). Justification for these groupings was based on sample size, thus there is no explicit explanation as to why utility differences between these groups would be expected.NANANANAWallander et al. (2009) \[[@CR59]\]Adults treated for CTEV in infancyMale participants had significantly higher average utility score than the comparable norm group (*p* = 0.027). Male participants reported significantly less moderate/extreme problems with anxiety/depression than the comparable norm group (6.3% vs 21.2%; *p* = 0.007).Female participants had worse utility on average than a comparable norm group, but not significantly. Female participants reported significantly more moderate/extreme problems with mobility (45% vs 12.2%; *p* \< 0.001) and usual activities (35% vs 12.5%; *p* = 0.006) than a comparable norm group.NANANANAYoung et al. (2010) \[[@CR22]\]Adolescents and young adults with cerebral palsyIn both the 'youth' and 'adult' groups, utility scores deteriorated steadily as GMFCS level increased. Statistical significance not reportedLinear regression analysis revealed that GMFCS level in childhood was the most important influence on utility scores; responsible for 53.2% of variance in HUI3 utility outcomes (β = − 0.205; *p* \< 0.001) and 45.2% of variance in AQoL utility outcomes (β = − 0.148; *p* \< 0.001).The SRH was found to be moderately correlated with utility scores derived from the HUI3 (*r =* 0.41; *p* \< 0.001) and AQoL (*r =* 0.41; *p* \< 0.001).Utility scores derived from HUI3 were on average higher than those derived from AQoL across all GMFCS levels; however strong correlation was found between the HUI3 and AQoL (*r =* 0.87; *p* \< 0.001).Proxy utility scores were generally lower (by 0.16) when adjusted for cognition, general health and CP severity. Statistical significance not reported.NAYoung et al. (2013) \[[@CR21]\]Adolescents and young adults with spina bifidaUtility scores derived from both HUI3 and AQoL varied in the same way according to lesion level, with thoracic lesions associated with lowest utility. Linear regression analysis revealed that the most important single factor contributing to utility outcomes was surgical lesion level; responsible for 40% of variance in HUI3 utility scores and 18% in AQoL utility scores. Both lesion level and age were important when combined, accounting for 48% variance in HUI3 utility scores and 22% variance in AQoL utility scores.The SRH was found to be moderately/strongly correlated with utility scores derived from the HUI3 (*r =* − 0.45; *p* \< 0.001) and AQoL (*r =* − 0.58; p \< 0.001). The HAQ was also strongly correlated with utility scores derived from the HUI3 (*r =* 0.79; *p* \< 0.001) and AQoL (*r =* 0.70; *p* \< 0.001).Utility scores derived from the AQoL were higher than from the HUI3 across all lesion level sub-groups; however the AQoL and HUI3 exhibited strong correlation (*r =* 0.73; *p* \< 0.001).Mean utility scores were slightly higher in the self-reported group (HUI3 mean + 0.04; AQoL mean + 0.03) however this was based on the comparison of youth and adult data and the regression models remained unchanged.NA

Cerebral palsy {#Sec19}
--------------

### Known-group analyses {#Sec20}

Five studies reported known-group analyses in CP \[[@CR22], [@CR33], [@CR51], [@CR53], [@CR58]\]. Petrou and Kupek \[[@CR51]\] estimated that the adjusted HUI3 disutility of childhood CP from perfect health was − 0.72 (95% confidence interval \[CI\] -0.61 to − 0.85), and − 0.65 (95% CI − 0.54 to − 0.78) from childhood norms. Two studies found that as CP severity (i.e. gross motor function) increased, average utility scores (measured using HUI3 or AQoL) decreased in adolescents and young adults with CP \[[@CR22], [@CR53]\]; Rosenbaum et al. \[[@CR53]\] found statistically significant differences in mean utility scores between most Gross Motor Function Classification System (GMFCS) levels (p \< 0.01). One study demonstrated that the vision, pain and cognition dimensions of the HUI3 steadily declined as GMFCS level increased, however statistical significance was not reported \[[@CR33]\]. Vitale et al. \[[@CR58]\] found that adolescents with CP had significantly higher average EQ-5D utility scores (0.92) compared to adolescents with scoliosis (with comorbidities) (0.73; *p* \> 0.05), although selection of these patient sub-groups was not explicitly justified and the version of the EQ-5D was not reported.

### Convergent validity: comparing measures {#Sec21}

Two studies reported that GMFCS level was correlated with worsening utility scores \[[@CR22], [@CR53]\]. Young et al. \[[@CR22]\] found that GMFCS level in childhood was responsible for between 45% (AQoL: β = − 0.148; *p* \< 0.001) and 53% (HUI3: β = − 0.205; *p* \< 0.001) of variance in utility scores. Rosenbaum et al. \[[@CR53]\] found a strong negative correlation between the HUI3 utility scores of adolescents with CP and their GMFCS level (*r* = − 0.81). In terms of individual PBM dimensions, results from four studies were varied \[[@CR33], [@CR35], [@CR39], [@CR49]\]; Kennes et al. \[[@CR39]\] found that the dimension most associated with GMFCS level in children was ambulation (tau-b = 0.82; *p* \< 0.01). Bartlett et al. \[[@CR33]\] found that the HUI3 vision, pain and cognition dimensions generally worsened as GMFCS level increased in adolescents; however, there was no indication that these dimensions were determinants of motor capacity decline. Two studies \[[@CR35], [@CR49]\] reported a significant negative association between the HUI3 pain dimension and GMFCS level in children with CP, however both of these studies only examined the HUI3 pain dimension and not the full HUI3 system.

Three studies reported various levels of correlation between PBMs and other outcome measures in CP \[[@CR22], [@CR46], [@CR53]\]. Young et al. \[[@CR22]\] found moderate correlation between utility score and SRH (*r* = 0.41; *p* \< 0.001 for both the HUI3 and AQoL). Two studies compared the Quality of Life Instrument for People with Developmental Disabilities (QOL Instrument) and the HUI3 \[[@CR46], [@CR53]\]; Rosenbaum et al. \[[@CR53]\] reported that adolescents' HUI3 utility scores explained between 3% (belonging) and 14% (being) of variance in QOL Instrument dimension scores, while Livingston and Rosenbaum \[[@CR46]\] reported that the HUI3 and QOL Instrument shared up to 23% variance, thus the relationship between the measures was considered to be moderate at best.

Two studies reported on the relationship between different PBMs in CP \[[@CR22], [@CR57]\]. Although utility scores derived from the HUI3 and AQoL were strongly correlated (*r* = 0.87; *p* \< 0.001) \[[@CR22]\], HUI3 derived utility scores tended to be lower than AQoL derived utility scores \[[@CR22], [@CR57]\].

### Convergent validity: comparing respondents {#Sec22}

Four studies examined correlation between respondents in CP \[[@CR22], [@CR48]--[@CR50]\]. Morrow et al. \[[@CR48]\] reported moderate agreement between parents and doctors of children with CP for the HUI2/3 dimensions of sensation (63.6% agreement; Kappa 0.41), cognition (70% agreement; Kappa 0.56), self-care (100% agreement; Kappa 1.00) and ambulation (63.6% agreement; Kappa 0.46). Good correlation was also found between child self-reported HUI3 pain scores and equivalent parent proxy scores (Goodman and Kruskal's y statistic = 0.57; *p* \< 0.001) \[[@CR49]\].

Perez Sousa et al. \[[@CR50]\] reported a high level of disagreement between parents and children on the EQ-5D youth version (EQ-5D-Y); parents reported a lower frequency of problems on all EQ-5D-Y proxy dimensions, particularly fathers.

### Responsiveness {#Sec23}

Five studies allowed analysis of PBM responsiveness in CP \[[@CR33], [@CR35], [@CR46], [@CR55], [@CR57]\]. Adolescents with a GMFCS level of V exhibited the largest decreases in HUI3 dimension levels over time, compared to adolescents with GMFCS levels of III and IV \[[@CR33]\]. Christensen et al. \[[@CR35]\] reported a significant association between physicians' primary pain aetiology and change in HUI3 pain status (*p* = 0.001). Conversely, in two studies utility outcomes did not change significantly over time; HUI3 utility outcomes were found to be stable over a 1 year period for adolescents with CP (G = 0.91) \[[@CR46]\], likewise utility outcomes (derived from HUI3 and AQoL) did not significantly change over an 8 year follow-up period \[[@CR57]\]. Slaman et al. \[[@CR55]\] utilised the SF-6D in a randomised controlled trial, but did not find a significant difference between the control and intervention groups at the end of the trial (*p* = 0.42).

Spina bifida {#Sec24}
------------

### Known-group analyses {#Sec25}

Three studies reported known-group analyses in SB \[[@CR51], [@CR52], [@CR56]\], two of which found that clinical factors had a significant impact on utility scores. Petrou and Kupek \[[@CR51]\] estimated that the adjusted HUI3 disutility of childhood SB from perfect health was − 0.55 (95% CI − 0.40 to − 0.70), and − 0.48 (95% CI − 0.33 to − 0.63) from childhood norms. A statistically significant effect of SB diagnosis on HUI3 utility score (*p* \< 0.001) was reported \[[@CR52]\]; children diagnosed with myelomeningocele (mean utility score = 0.51) tended to have lower utility scores compared to children with closed dysraphism (mean utility score = 0.77). Tilford et al. \[[@CR56]\] reported that lesion location in childhood SB had a significant impact on overall utility (*p* \< 0.01); individuals with sacral lesions had the highest overall mean utility (0.61; ±0.26).

Two studies reported correlation between clinical factors and utility scores in SB \[[@CR21], [@CR38]\]. Anatomical myelomeningocele level was found to have a significant effect on the HUI utility scores of children with myelomeningocele and shunted hydrocephalus (mean HUI score = 0.03; 95% CI 0.01 to 0.05; *p* = 0.01) \[[@CR38]\], with lower myelomeningocele level showing association with higher utility scores. A similar trend was reported by Young et al. \[[@CR21]\], who found that the most important single factor contributing to utility outcomes in SB was surgical lesion level, which was responsible for between 18% (AQoL) and 40% (HUI3) of variance in utility scores.

### Convergent validity: comparing measures {#Sec26}

Two studies reported various levels of correlation between PBMs and other outcome measures in SB \[[@CR21], [@CR54]\]. Child self-reported HUI3 utility scores were not found to be highly correlated with VAS scores (*r* = 0.488) \[[@CR54]\]. Likewise, the SRH was only moderately correlated with utility scores in SB (HUI3: *r* = − 0.45; *p* \< 0.001 / AQoL: *r* = − 0.58; *p* \< 0.001) \[[@CR21]\]. Only the HAQ was found to be strongly correlated with utility score (HUI3: *r* = 0.79; *p* \< 0.001 / AQoL: *r* = 0.70; *p* \< 0.001) \[[@CR21]\].

Young et al. \[[@CR21]\] compared results from different PBMs in SB, and found that mean utility scores on the AQoL were lower than mean utility scores on the HUI3 for all sub-groups, despite strong correlation between these measures (*r* = 0.73; *p* \< 0.001).

### Convergent validity: comparing respondents {#Sec27}

Sims-Williams et al. \[[@CR54]\] reported that proxy and self-reported HUI3 utility scores were highly correlated for children with SB (*r* = 0.85; significance not reported). Young et al. \[[@CR21]\] found that mean self-reported utility scores were slightly higher than equivalent proxy scores (HUI3 mean + 0.04; AQoL mean + 0.03) however respondent type was not influential in their regression analysis.

PBM responsiveness outcomes in SB were not found in the literature.

Mixed patient groups and mobility impairments {#Sec28}
---------------------------------------------

This section includes results from studies which did not focus on specific conditions, and where sub-group data could not be examined separately. Relevant conditions/mobility impairments included muscular dystrophy, spinal muscular atrophy, CP, SB, orthopaedic lower limb deformities, artrogryposis multiple congenital, achondroplasia and hemiplegia.

### Known-group analyses {#Sec29}

Two studies reported known-group analyses in studies of mixed patient groups \[[@CR11], [@CR51]\]. Petrou and Kupek \[[@CR51]\] found that children with muscular dystrophy or spinal muscular atrophy had a mean utility score of 0.39, equating to an adjusted disutility from perfect health of − 0.62 (95% CI − 0.471 to − 0.761), and an adjusted disutility from childhood norms of − 0.54 (95% CI − 0.400 to − 0.690). Burstrom et al. \[[@CR11]\] reported that children with a functional disability (64% congenital; see Table [4](#Tab4){ref-type="table"} for patient characteristics) had significantly lower EQ-5D-Y dimension scores than the general population (*p* \< 0.001).

### Convergent validity: comparing outcomes {#Sec30}

Moderate correlation was found between the individual dimensions of the EQ-5D-Y and the dimensions of other measures (KIDSCREEN-27 and KIDSCREEN-10) and the life satisfaction ladder (LSL), when completed by children with functional disabilities \[[@CR11]\] . The EQ-5D-Y anxiety/depression dimension exhibited significant correlation with the KIDSCREEN-27 psychological well-being dimension (*r* = − 0.51; p = 0.001), the KIDSCREEN-27 physical well-being dimension (*r* = − 0.53; *p* = 0.001), and the LSL (*r* = − 0.54; *p* \< 0.001) \[[@CR11]\].

Large variance was observed between utility scores derived from different PBMs for young wheelchair users; mean utility scores ranged from 0.24 (EQ-5D-Y) to 0.53 (HUI2) for self-reporting children, and from 0.01 (EQ-5D-Y) to 0.49 (HUI2) for parent proxies \[[@CR15]\].

### Convergent validity: comparing respondents {#Sec31}

A significant strong correlation was observed between dyads of young wheelchair users (84.6% children with CP, see Table [4](#Tab4){ref-type="table"} for patient characteristics) and parent proxies for a number of utility measures: EQ-5D-Y (*r* = 0.67; *p* = 0.026), HUI2 (*r* = 0.73; *p* = 0.005) and HUI3 (*r* = 0.84; *p* \< 0.001) \[[@CR15]\]. Using Bland-Altman plots \[[@CR60]\], sufficient agreement was observed between dyads for the HUI2 (CL = 0.22) and HUI3 (CL = 0.22), but not the EQ-5D-Y (CL = 1.04). A significant respondent type effect was found for all measures, with child self-reported utility scores significantly higher for the EQ-5D-Y (*p* = 0.012), HUI2 (*p* = 0.021) and HUI3 (*p* = 0.009) than equivalent proxy measures \[[@CR15]\].

PBM responsiveness outcomes were not found in the literature for this patient group.

Childhood hydrocephalus (mixed aetiology) {#Sec32}
-----------------------------------------

### Known-group analyses {#Sec33}

Lindquist et al. \[[@CR45]\] found that adults with a history of hydrocephalus (with or without neuro-impairment) had significantly lower 15D dimension scores, compared to a control group, in the dimensions of vision (*p* = 0.001), eating (*p* = 0.000), usual activities (*p* = 0.004) and mental function (*p* = 0.000).

### Convergent validity: comparing measures {#Sec34}

Four studies examined the relationship between the Hydrocephalus Outcome Questionnaire (HOQ) and PBMs \[[@CR40]--[@CR43]\], however only three of these studies performed relevant statistical analyses \[[@CR40], [@CR41], [@CR43]\]. Kulkarni \[[@CR41]\] reported strong correlation (0.81) and a strong linear relationship between HUI2 utility score and HOQ outcomes for children with hydrocephalus. Simple and complex linear regression models both accounted for a large proportion of HUI2 variability (adjusted R^2^ = 0.66 and 0.80 respectively). Similarly, a strong correlation was found between HUI2 utility score and the HOQ scores for overall health (*r* = 0.81), physical health (*r* = 0.88), social-emotional (*r* = 0.56) and cognitive (*r* = 0.57) \[[@CR40]\]. Furthermore, a significant positive correlation was exhibited between self-reported scores on the child-completed version of the HOQ (cHOQ) and proxy-reported utility scores on the HUI3 (*r* = 0.60; *p* \< 0.001) \[[@CR43]\].

PBM responsiveness outcomes in childhood hydrocephalus were not found in the literature.

Other conditions and mobility impairments {#Sec35}
-----------------------------------------

Only known-group analyses were reported for the following conditions associated with mobility impairment:

### Muscular dystrophy {#Sec36}

Landfeldt et al. \[[@CR44]\] reported that ambulatory status and age were significantly associated with HUI utility scores in muscular dystrophy (HUI version not stated; p \< 0.001); young ambulators (5--7 years old) had the highest utility scores on average (0.75), whilst older non-ambulators (≥16 years old) had the lowest utility scores on average (0.15).

### Spinal muscular atrophy {#Sec37}

Lopez-Bastida et al. \[[@CR47]\] reported that children with Type II spinal muscular atrophy tended to have lower mean proxy utility scores (− 0.01; ±0.35) than the combined average for all forms of spinal muscular atrophy (0.16; ±0.44), however statistical analysis was not undertaken.

### Morquio A syndrome {#Sec38}

One study found that for both adults and children with Morquio A syndrome, wheelchair use was significantly associated with lower utility scores \[[@CR37]\]. Significant differences were reported in the adult group between non-wheelchair users and occasional wheelchair users (*p* = 0.0115) and between occasional wheelchair users and full-time wheelchair users (*p* = 0.0007). In the child group significant differences were reported between non-wheelchair users and full-time wheelchair users (*p* = 0.0018) and occasional wheelchair users and full-time wheelchair users (*p* = 0.0007).

### Congenital clubfoot {#Sec39}

Wallander et al. \[[@CR59]\] found that male adult patients with congenital clubfoot (CCF) had significantly better overall utility scores than the male norm group (p = 0.027). The female CCF group had a lower average utility score than the norm group, but not significantly (significance level not reported).

### Microcephaly {#Sec40}

Petrou and Kupek \[[@CR51]\] found that children with microcephaly had a mean utility score of 0.14, equating to an adjusted disutility from perfect health of − 0.82 (95% CI − 0.67 to − 0.97), and an adjusted disutility from childhood norms of − 0.75 (95% CI − 0.60 to − 0.90).

Discussion {#Sec41}
==========

The results from this systematic review demonstrate that PBMs have been used in a relatively small number of studies relating to congenital mobility impairments. In conditions such as CP and SB, increased clinical severity appears to be associated with decreased utility. This is particularly evident using the HUI3, which was also the most commonly used PBM found in this review. In particular, there appears to be a relationship between utility outcomes and GMFCS level in CP, and clinical factors such as lesion level in SB. In case-control studies, utility outcomes tended to be significantly lower in the case groups, although it is worth noting that in one study the male case-group had significantly higher utility outcomes compared to the control \[[@CR59]\].

In order to demonstrate sufficient applicability and sensitivity in a specific disease or disability, association between PBMs and validated clinical/condition-specific outcomes is of key importance. In this respect existing PBMs show weakness in various conditions associated with congenital mobility impairments; exhibiting generally limited correlation with measures such as the QOL Instrument, VAS, SRH, KIDSCREEN-27, KIDSCREEN-10 and LSL. Only the GMFCS and HOQ/cHOQ appeared to be well correlated with PBMs across a number of studies, although it is important to note that GMFCS is a classification system of gross motor function and not an outcome measure.

The results from this systematic review highlight important considerations for the use of PBMs in health states associated with congenital mobility impairment. It is first of note that the use of PBMs has been dominated by studies in CP, followed by SB. This is somewhat unsurprising given that these are two of the most prevalent congenital disabilities which affect mobility. Secondly, it is important to acknowledge that only two studies focussed on adults alone, and that both of these studies were measuring utility outcomes in adults following conditions experienced in childhood \[[@CR45], [@CR59]\]. This focus on children and adolescents is again unsurprising, as many congenital conditions can be life-limiting, thus examining health outcomes at a young age becomes particularly important. However, this also shows a lack of focus on the health outcomes of adults who have life-long experience of mobility impairment, and the potential ways in which their health outcomes could change over time or be improved.

There is some evidence to demonstrate that different PBMs vary in their estimation of utility outcomes in states of impaired mobility. For instance, Bray et al. \[[@CR15]\] found large variation between the EQ-5D-Y and HUI2/3 utility scores for wheelchair users. Likewise, Usuba et al. \[[@CR57]\] and Young et al. \[[@CR21], [@CR22]\] found that utility outcomes were generally higher when derived from the AQoL than the HUI3 for individuals with CP, but vice versa for individuals with SB. This is despite the strong correlation between the AQoL and HUI3 in these populations \[[@CR21], [@CR22]\]. Unfortunately, statistical differences between these measures were not reported, but it is still important to consider the implications that these differences could have on subsequent QALY outcomes. For instance, if one PBM were to produce significantly higher utility scores than another, this would mean significantly different estimates of cost per QALYs and thus estimates of cost-effectiveness. At present there is limited evidence to enable health economists and researchers to choose between these different PBMs for use in congenital mobility impairments.

Despite documented limitations \[[@CR61]\], QALYs have become increasingly influential in health policy as a means to determine the cost-effectiveness of new treatments and services, and therefore guide healthcare funding and prioritisation decisions. It is therefore imperative that the PBMs used to develop QALYs are accurate. Otherwise, the cost-effectiveness of certain interventions in certain patient groups could be underestimated. This in turn could impact funding and prioritisation decisions. In the context of congenital mobility impairment, this could impact the provision of AMT and other mobility-enhancing interventions, and subsequently impact patient outcomes. This is particularly important considering the ongoing issues of unmet need in assistive technology provision. The WHO Priority Assistive Products List (APL) was launched in 2016 to help tackle unmet need \[[@CR62]\]. The APL contains 50 priority assistive technology products, and was produced through consultation with users, experts and other key stakeholders. Appropriate PBM data, and subsequent estimates of cost-effectiveness, could help to inform the APL and ensure that the most effective and cost-effective AMTs are prioritised.

Considering that the majority of evidence found in this review related to children, the relationship between self-reported and proxy utility outcomes is particularly significant. The results from various studies in this review demonstrate that proxy-reporting of utility is consistently different to that of self-reporters, including significant respondent-type effects and limited agreement between respondents. Interestingly, proxy respondents were found to both underestimate and overestimate utility outcomes compared to self-reporters. It is therefore important to prioritise outcome measurement from the patient, although this can be challenging in populations who may lack capacity, such as young children and individuals with cognitive impairments.

Methodological implications {#Sec42}
---------------------------

Due to the underlying trade-off between quantity and quality of life in the calculation of utility values and subsequent QALYs, there is a tendency for lower value to be placed on extending the length of life of people with long-term disabilities \[[@CR10], [@CR63]\], as their quality of life is routinely considered to be worse than that of an able-bodied person. Thus, when using the QALY framework to assess the outcomes of individuals with disabilities, it is difficult to achieve substantially higher quality of life when compared to individuals without disabilities, raising concerns about bias \[[@CR10]\]. To some extent these issues could be a result of using generic PBMs to value disabled health states.

One of the underlying issues of using PBMs in disability is that the definition of HRQoL differs profoundly between people with disabilities and the general public \[[@CR64]\]. When asked to define HRQoL, young wheelchair users focus on a number of concepts not explicitly measured using generic PBMs, such as ability to adapt, achievement and independence \[[@CR17]\]. The experience of disability also affects HRQoL perceptions. Mechanisms of adaptation, coping and adjustment can help individuals with disabilities to experience diminishing effects to their HRQoL over time. These processes are also influenced by the onset of disability, as individuals with congenital disabilities demonstrate better adaptation than individuals with acquired disabilities \[[@CR2]\]. The evaluation of states of disability by non-disabled individuals may therefore cause such states to have an exaggerated perceived impact on HRQoL and health status \[[@CR65]\], particularly with regards to congenital disability.

When assessing the desirability of hypothetical health states, individuals focus on the transition from their own health state to the hypothetical health state, thus general public beliefs about the impact of disability do not always reflect the lived experience \[[@CR66], [@CR67]\]. Focus on personal transition means that processes such as adaptation are not accounted for, causing a discrepancy in how states of disability impact HRQoL \[[@CR9]\].

An alternative approach is to use more sensitive condition-specific measures to model utility values on generic PBMs. Although this approach is advocated by NICE \[[@CR68]\] there are serious concerns about the validity of modelled utility values \[[@CR69]\], as it cannot be assumed that modelled utility values are representative of directly measured utility values \[[@CR70]\]. Using modelled utility data to guide funding and resource allocation decisions is therefore controversial. For instance, Sidovar et al. \[[@CR71]\] mapped the 12-Item Multiple Sclerosis Walking Scale (MSWS-12) onto the EQ-5D-3 L. While prediction estimates were relatively precise for patients with moderately impaired mobility, they were significantly less accurate for individuals with severe impairments.

Neilson et al. \[[@CR72]\] suggest supplementing PBMs with additional questions relating to functional activities which have a large impact on overall quality of life, such as 'sitting' for AMT users. For instance, Persson et al. \[[@CR73]\] added complimentary mobility and social relationship items to the EQ-5D-3 L to increase sensitivity in disabled populations. However, this approach assumes that supplemental questions can be mapped on to the health state preference values of existing measures without impacting accuracy.

Limitations and challenges {#Sec43}
--------------------------

Defining the term congenital mobility impairment was one of the key challenges of designing this systematic review. An NHS posture and mobility service manager was consulted to help construct the search terms, and a number of preliminary searches were carried out to test search terms for both sensitivity and scope. A multitude of conditions and disabilities can affect mobility from birth or early infancy, thus we attempted to cover a wide variety of these in our search terms, but accept that there are likely to be conditions and disabilities which were missed. Given the search results, we are confident that we have captured the vast majority of relevant studies relating to at least the most common forms of congenital mobility impairment. One key issue was considering whether to include studies relating to hydrocephalus in this review. Although hydrocephalus is not always associated with mobility impairment, it can cause movement issues and is commonly related to relevant conditions such as CP and SB. We therefore chose to include studies related to childhood hydrocephalus.

We chose specifically to focus on congenital mobility impairment due to the significant differences in life satisfaction, self-identity and self-efficacy experienced by people with congenital disabilities compared to people with acquired disabilities \[[@CR2]\]. Further research could compare PBM performance in congenital and acquired mobility impairments. Previous reviews have reported mixed results regarding the validity and responsiveness of existing PBMs in the assessment of health states associated with acquired mobility impairments, such as rheumatoid arthritis \[[@CR24]\] and multiple sclerosis \[[@CR26]\].

Conclusion {#Sec44}
==========

To our knowledge, this is the first systematic review of the use of PBMs in congenital mobility impairment. Evidence suggests that existing generic PBMs exhibit important issues relating to validity and responsiveness, and thus care must be taken when selecting a PBM as an outcome measure in this context. Condition or disability specific approaches to utility measurement, such as the mobility and quality of life (MobQoL) outcome measure \[[@CR74]\], could improve the sensitivity and applicability of utility measurement in this context.
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